At the end of the third quarterly report, what kind of "answer sheet" did pharmaceutical equipment companies hand over?

【Pharmaceutical Network Market Analysis】A few days ago, the third quarterly report of listed pharmaceutical equipment companies in 2022 has basically ended, and the overall performance is stable and good, of which the operating income and net profit of the first three quarters represented by Chutian Technology, Dongfulong and other leading enterprises have achieved year-on-year growth
.
At the end of the third quarterly report, what kind of "answer sheet" did pharmaceutical equipment companies hand over? (Image source: Pharma Network) The performance of the head pharmaceutical machine enterprises grew steadily in the first three quarters In the face of the complex domestic and foreign environment, the operation of pharmaceutical equipment enterprises has shown good development resilience, and the performance of leading enterprises such as Chutian Technology and Dongfulong has grown
steadily in the first three quarters 。 On October 25, Chutian Technology released the third quarter report of 2022, in the first three quarters, the company achieved operating income of about 4.
495 billion yuan, a year-on-year increase of 22.
06%%; The net profit attributable to shareholders of listed companies was about 463 million yuan, a year-on-year increase of 15.
32%; The net profit attributable to shareholders of listed companies before non-recurring profits and losses was about 451 million yuan, a year-on-year increase of 21.
39%.

In the third quarter alone, the company achieved operating income of 1.
624 billion yuan, a year-on-year increase of 25.
81%; the net profit attributable to shareholders of listed companies was 163 million yuan, a year-on-year decrease of 1.
03%; The net profit attributable to shareholders of listed companies before non-recurring profits and losses was 157 million yuan, a year-on-year increase of 14.
76%.

On October 28, Dongfulong disclosed the third quarterly report, the company's revenue in the first three quarters, net profit attributable to shareholders of listed companies, net profit attributable to shareholders of listed companies net of non-recurring profits and losses of 3.
817 billion yuan, 604 million yuan and 566 million yuan, respectively, an increase of 32.
43%, 8.
29% and 10.
92%
year-on-year 。 Among them, in the third quarter, Dongfulong achieved revenue income, net profit attributable to shareholders of listed companies, and net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses of 1.
390 billion yuan, 202 million yuan and 195 million yuan respectively, a year-on-year increase of 29.
60%, -7.
38% and 4.
59%
respectively.
As for the reasons affecting net profit, Dongfulong mentioned that it mainly includes several aspects: rising raw material prices (especially overseas imported components); The company simultaneously strengthens and reserves personnel in all links of research and development, management, sales, manufacturing and service, and increases labor costs and various expenses accordingly
.
On the same day, Canaan Technology also released its third quarterly report, the company's total operating income in the first three quarters was 757 million yuan, a year-on-year increase of 0.
7%, but the net profit decreased by 34.
21%.

The analysis believes that relatively speaking, the performance of the pharmaceutical equipment industry in the first three quarters of this year has been differentiated, and the head enterprises have performed better overall by virtue of their forward-looking layout in the field of biological drugs, continuous improvement of product strength, and better cost control, while small and medium-sized pharmaceutical machinery enterprises are weak in cost control and other aspects, and the impact of the environment is also more obvious
.
The industry as a whole shows a strong momentum of development Under the background of the overall improvement of the third quarterly report, the head enterprises actively develop in the direction of high quality, increase investment in research and development, and reflect strong development vitality
.
From the perspective of R&D investment, from the beginning of the year to the end of the reporting period, the company's R&D expenses were 375 million yuan, an increase of 68 million yuan over the same period of the previous year of 307 million yuan
.
It is worth mentioning that the company's development expenditure from January to September was 50.
8461 million yuan, an increase of 14.
7406 million yuan or 40.
83% over the beginning of the period, mainly due to the increase in
new product research and development investment of its subsidiary Romaco Group.
Romaco Group, a large German pharmaceutical machinery company acquired by Chutian Technology, replied to investors on the interactive platform in September, saying, "Romaco Group has continued to increase
orders in hand while the same industry in Europe has declined year-on-year.
" This year's new orders increased by more than
10% year-on-year.
However, it also mentioned that this year was affected by various force majeure forces, which affected the production and delivery of the Romaco Group, which in turn affected the operating results
.
The Romaco Group will strive to meet the performance commitments
made in the event of the merger and acquisition.
According to the third quarterly report of Dongfulong, the company's R&D expenses in the first three quarters increased by 39.
77% compared with the same period of the previous year, mainly due to the company's increase in R&D investment in the current period, the increase in R&D personnel, and the increase in
the number of R&D projects.
It is reported that during the reporting period, the company continued to promote the diversified layout of products and the strategy of internationalization, through the introduction of high-end talents in the industry, the establishment of a technology platform for research and development, pilot scale-up and large-scale production, R&D investment was continuously strengthened, and the scale of products gradually expanded
.
In addition, although the performance of Canaan Technology in the first three quarters of this year has been under pressure, the company still attaches great importance to R&D investment, and the company's R&D expenses in the first three quarters of this year were 53.
9878 million yuan, an increase of 6.
4958 million yuan compared with 47.
492 million yuan
in the same period of the previous year.
Conclusion "The current pharmaceutical equipment industry is facing a complex environment, and some raw material prices have risen and labor costs have risen, but with the rapid development of the upstream biopharmaceutical industry and the support of favorable policies, the overall development momentum is still relatively strong
.
" The industry believes that the pharmaceutical equipment industry is an important industry related to the level of China's pharmaceutical industry, as pharmaceutical machinery enterprises continue to increase investment, the future will continue to break through in the high-end field, break the long-term monopoly of imported equipment market situation, improve the competitive advantage of domestic pharmaceutical machinery, and inject more confidence
into accelerating import substitution.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.